Resatorvid

Resatorvid (TAK-242) is a cyclohexane derivative that was invented by scientists at Takeda in a drug discovery campaign to identify inhibitors of the receptor TLR4.^[1] It binds directly to cysteine residue 747^[1] intracellularly, preventing TLR4 binding with TIRAP and thus preventing downstream signal transduction.^[2]

Resatorvid

Clinical data
Trade names	Resatorvid
Identifiers
IUPAC name ethyl (6R)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohexene-1-carboxylate
CAS Number	243984-11-4
PubChem CID	11703255
DrugBank	05943
ChemSpider	9877978
UNII	H2MZ648C31
ChEMBL	ChEMBL225157
CompTox Dashboard (EPA)	DTXSID00947269
Chemical and physical data
Formula	C15H17ClFNO4S
Molar mass	361.81 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)NC2=C(C=C(C=C2)F)Cl
InChI InChI=1S/C15H17ClFNO4S/c1-2-22-15(19)11-5-3-4-6-14(11)23(20,21)18-13-8-7-10(17)9-12(13)16/h5,7-9,14,18H,2-4,6H2,1H3/t14-/m1/s1 Key:LEEIJTHMHDMWLJ-CQSZACIVSA-N

A randomized, double-blinded Phase III trial of resatorvid in sepsis was halted early due to lack of efficacy, and the compound has become a widely used tool compound in biological research.^[1]

It has antiinflammatory and neuroprotective effects in preclinical models.^[3] It has been explored in preclinical studies of several forms of cancer, including multiple myeloma, breast cancer, and ovarian cancer,^[4] and has been suggested for study in skin cancers.^[5]

Efforts have been made to improve resatorvid by making prodrugs and deuterated derivatives.^[3]

See also

• M62812
• TLR4-IN-C34